Fenofibrates: A Safe and Novel Weapon Against Coronavirus‑Induced Lung Fibrosis

Mohammad Mahdi Parvizi


Dear Editor, Coronavirus‑19 is a novel virus involving humans and animals in the world.[1] According to chest radiography and chest computerized tomography (CT) scan, the lungs of patients with COVID‑19 are infiltrative prone to lung fibrosis that may result in death.[2] Therefore, prevention and early treatment of lung fibrosis are critical.


Fenofibrates; Coronavirus‑Induced Lung Fibrosis; COVID-19

Full Text:



Kutti‑Sridharan G, Vegunta R, Vegunta R, Mohan BP,

Rokkam VR. SARS‑CoV2 in different body fluids, risks of

transmission, and preventing COVID‑19: A comprehensive

evidence‑based review. Int J Prev Med 2020;11:97.

Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N,

et al. Chest CT findings in coronavirus disease‑19 (COVID‑19):

Relationship to duration of infection. Radiology 2020;295:200463.

Epstein Shochet G, Brook E, Bardenstein-Wald B, Shitrit D.

TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF)

fibroblast derived soluble factors is mediated by IL-6 transsignaling. Respiratory Research. 2020;21.

Keating GM, Croom KF. Fenofibrate. Drugs 2007;67:121‑53.

Wahba MG, Messiha BA, Abo‑Saif AA. Protective effects of

fenofibrate and resveratrol in an aggressive model of rheumatoid

arthritis in rats. Pharm Biol 2016;54:1705‑15.

Lv J, Wang X, Liu S, Liang P, Feng M, Zhang L, et al.

Protective effect of Fenofibrate in renal ischemia reperfusion

injury: Involved in suppressing kinase 2 (JAK2)/transcription

(STAT3)/p53 signaling activation. Pathol Biol 2015;63:236‑42.

Alleva L, Budd A, Clark I. Minimising influenza disease with

fibrates. Int J Infect Dis 2008;12:e176.